Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled
A pivotal Phase 3 study investigating melflufen (melphalan flufenamide)…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo
The U.K.’s National Institute for Health and Care…
Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients
Karyopharm Therapeutics is asking that Xpovio (selinexor)…
New Under-the-skin Darzalex Formulation Approved in EU
The European Commission (EC) has approved a new…
Sarclisa Triple Combo Approved in Europe for Advanced Myeloma Patients
The European Commission (EC) has approved Sanofi‘s…
CHMP Favors Darzalex Faspro in Treating Patients in EU
Janssen‘s new under-the-skin formulation…
